JP2011521949A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011521949A5 JP2011521949A5 JP2011511661A JP2011511661A JP2011521949A5 JP 2011521949 A5 JP2011521949 A5 JP 2011521949A5 JP 2011511661 A JP2011511661 A JP 2011511661A JP 2011511661 A JP2011511661 A JP 2011511661A JP 2011521949 A5 JP2011521949 A5 JP 2011521949A5
- Authority
- JP
- Japan
- Prior art keywords
- xaa
- ser
- pharmaceutically acceptable
- ala
- trp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 claims description 46
- 150000001875 compounds Chemical class 0.000 claims description 37
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims description 32
- 150000003839 salts Chemical class 0.000 claims description 25
- 239000011780 sodium chloride Substances 0.000 claims description 25
- AGPKZVBTJJNPAG-RFZPGFLSSA-N D-isoleucine Chemical compound CC[C@@H](C)[C@@H](N)C(O)=O AGPKZVBTJJNPAG-RFZPGFLSSA-N 0.000 claims description 24
- HNDVDQJCIGZPNO-RXMQYKEDSA-N D-histidine Chemical compound OC(=O)[C@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-RXMQYKEDSA-N 0.000 claims description 18
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 claims description 18
- COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 claims description 16
- 125000000052 D-arginine group Chemical group [H]N([H])[C@@]([H])(C(=O)[*])C([H])([H])C([H])([H])C([H])([H])N([H])C(N([H])[H])=N[H] 0.000 claims description 12
- 125000000237 D-prolino group Chemical group [H]OC(=O)[C@]1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 12
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 claims description 12
- KZSNJWFQEVHDMF-SCSAIBSYSA-N D-valine Chemical compound CC(C)[C@@H](N)C(O)=O KZSNJWFQEVHDMF-SCSAIBSYSA-N 0.000 claims description 12
- 102000008314 Type 1 Melanocortin Receptor Human genes 0.000 claims description 12
- 108010021428 Type 1 Melanocortin Receptor Proteins 0.000 claims description 12
- 239000000546 pharmaceutic aid Substances 0.000 claims description 11
- 229920001184 polypeptide Polymers 0.000 claims description 10
- WHUUTDBJXJRKMK-GSVOUGTGSA-N D-glutamic acid Chemical compound OC(=O)[C@H](N)CCC(O)=O WHUUTDBJXJRKMK-GSVOUGTGSA-N 0.000 claims description 8
- FFEARJCKVFRZRR-SCSAIBSYSA-N D-methionine Chemical compound CSCC[C@@H](N)C(O)=O FFEARJCKVFRZRR-SCSAIBSYSA-N 0.000 claims description 8
- OUYCCCASQSFEME-MRVPVSSYSA-N D-tyrosine Chemical compound OC(=O)[C@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-MRVPVSSYSA-N 0.000 claims description 8
- 206010025650 Malignant melanoma Diseases 0.000 claims description 8
- 201000001441 melanoma Diseases 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 150000008575 L-amino acids Chemical class 0.000 claims description 6
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 claims description 6
- 206010003816 Autoimmune disease Diseases 0.000 claims description 5
- 201000009596 autoimmune hypersensitivity disease Diseases 0.000 claims description 5
- GTVVZTAFGPQSPC-MRVPVSSYSA-N (2R)-2-azaniumyl-3-(4-nitrophenyl)propanoate Chemical compound OC(=O)[C@H](N)CC1=CC=C([N+]([O-])=O)C=C1 GTVVZTAFGPQSPC-MRVPVSSYSA-N 0.000 claims description 4
- QADCERNTBWTXFV-JSGCOSHPSA-N Arg-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CCCNC(N)=N)N)C(O)=O)=CNC2=C1 QADCERNTBWTXFV-JSGCOSHPSA-N 0.000 claims description 4
- CKLJMWTZIZZHCS-UWTATZPHSA-N D-aspartic acid Chemical compound OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 claims description 4
- RHGKLRLOHDJJDR-SCSAIBSYSA-N D-citrulline Chemical compound OC(=O)[C@H](N)CCCNC(N)=O RHGKLRLOHDJJDR-SCSAIBSYSA-N 0.000 claims description 4
- 206010061218 Inflammation Diseases 0.000 claims description 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 4
- MIDZLCFIAINOQN-WPRPVWTQSA-N Phe-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=CC=C1 MIDZLCFIAINOQN-WPRPVWTQSA-N 0.000 claims description 4
- 230000000259 anti-tumor Effects 0.000 claims description 4
- 125000000267 glycino group Chemical group [H]N([*])C([H])([H])C(=O)O[H] 0.000 claims description 4
- 230000004054 inflammatory process Effects 0.000 claims description 4
- 206010052779 Transplant rejections Diseases 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- HKTRDWYCAUTRRL-UHFFFAOYSA-N 4-amino-5-[[1-carboxy-2-(1H-imidazol-5-yl)ethyl]amino]-5-oxopentanoic acid Chemical compound OC(=O)CCC(N)C(=O)NC(C(O)=O)CC1=CN=CN1 HKTRDWYCAUTRRL-UHFFFAOYSA-N 0.000 claims description 2
- 206010002967 Aplastic anaemia Diseases 0.000 claims description 2
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 2
- 206010003246 Arthritis Diseases 0.000 claims description 2
- 206010004161 Basedow's disease Diseases 0.000 claims description 2
- 206010009839 Coeliac disease Diseases 0.000 claims description 2
- 206010011401 Crohn's disease Diseases 0.000 claims description 2
- -1 D-Butionine Chemical compound 0.000 claims description 2
- 206010012601 Diabetes mellitus Diseases 0.000 claims description 2
- 102000033147 ERVK-25 Human genes 0.000 claims description 2
- 208000007882 Gastritis Diseases 0.000 claims description 2
- IKAIKUBBJHFNBZ-LURJTMIESA-N Gly-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)CN IKAIKUBBJHFNBZ-LURJTMIESA-N 0.000 claims description 2
- 208000003807 Graves Disease Diseases 0.000 claims description 2
- 201000004779 Graves' disease Diseases 0.000 claims description 2
- 206010020751 Hypersensitivity Diseases 0.000 claims description 2
- 206010021972 Inflammatory bowel disease Diseases 0.000 claims description 2
- 206010025135 Lupus erythematosus Diseases 0.000 claims description 2
- 108010060534 MSH (11-13) Proteins 0.000 claims description 2
- 206010028417 Myasthenia gravis Diseases 0.000 claims description 2
- 208000003067 Myocardial Ischemia Diseases 0.000 claims description 2
- 108091005771 Peptidases Proteins 0.000 claims description 2
- 210000002381 Plasma Anatomy 0.000 claims description 2
- 239000004365 Protease Substances 0.000 claims description 2
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims description 2
- PBUXMVYWOSKHMF-WDSKDSINSA-N Ser-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CO PBUXMVYWOSKHMF-WDSKDSINSA-N 0.000 claims description 2
- NHUHCSRWZMLRLA-UHFFFAOYSA-N Sulfizole Chemical compound CC1=NOC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1C NHUHCSRWZMLRLA-UHFFFAOYSA-N 0.000 claims description 2
- 231100000765 Toxin Toxicity 0.000 claims description 2
- 201000005794 allergic hypersensitivity disease Diseases 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 201000001320 atherosclerosis Diseases 0.000 claims description 2
- 201000004982 autoimmune uveitis Diseases 0.000 claims description 2
- 230000015556 catabolic process Effects 0.000 claims description 2
- 230000004059 degradation Effects 0.000 claims description 2
- 238000006731 degradation reaction Methods 0.000 claims description 2
- VPZXBVLAVMBEQI-VKHMYHEASA-N gly ala Chemical compound OC(=O)[C@H](C)NC(=O)CN VPZXBVLAVMBEQI-VKHMYHEASA-N 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- 239000003504 photosensitizing agent Substances 0.000 claims description 2
- 201000004681 psoriasis Diseases 0.000 claims description 2
- 239000002534 radiation-sensitizing agent Substances 0.000 claims description 2
- 108010071207 serylmethionine Proteins 0.000 claims description 2
- 239000003053 toxin Substances 0.000 claims description 2
- 108010038745 tryptophylglycine Proteins 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 9
- 230000002757 inflammatory Effects 0.000 claims 1
- 239000007943 implant Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5637308P | 2008-05-27 | 2008-05-27 | |
| US61/056,373 | 2008-05-27 | ||
| PCT/US2009/037809 WO2009151708A2 (en) | 2008-05-27 | 2009-03-20 | Peptide analogs of alpha-melanocyte stimulating hormone |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014150428A Division JP6170019B2 (ja) | 2008-05-27 | 2014-07-24 | α−メラニン形成細胞刺激ホルモンのペプチド類似体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011521949A JP2011521949A (ja) | 2011-07-28 |
| JP2011521949A5 true JP2011521949A5 (cs) | 2013-04-18 |
| JP5624027B2 JP5624027B2 (ja) | 2014-11-12 |
Family
ID=41278142
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011511661A Expired - Fee Related JP5624027B2 (ja) | 2008-05-27 | 2009-03-20 | α−メラニン形成細胞刺激ホルモンのペプチド類似体 |
| JP2014150428A Expired - Fee Related JP6170019B2 (ja) | 2008-05-27 | 2014-07-24 | α−メラニン形成細胞刺激ホルモンのペプチド類似体 |
| JP2017000343A Expired - Fee Related JP6585099B2 (ja) | 2008-05-27 | 2017-01-05 | α−メラニン形成細胞刺激ホルモンのペプチド類似体 |
| JP2019017752A Withdrawn JP2019065053A (ja) | 2008-05-27 | 2019-02-04 | α−メラニン形成細胞刺激ホルモンのペプチド類似体 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014150428A Expired - Fee Related JP6170019B2 (ja) | 2008-05-27 | 2014-07-24 | α−メラニン形成細胞刺激ホルモンのペプチド類似体 |
| JP2017000343A Expired - Fee Related JP6585099B2 (ja) | 2008-05-27 | 2017-01-05 | α−メラニン形成細胞刺激ホルモンのペプチド類似体 |
| JP2019017752A Withdrawn JP2019065053A (ja) | 2008-05-27 | 2019-02-04 | α−メラニン形成細胞刺激ホルモンのペプチド類似体 |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US8440793B2 (cs) |
| EP (2) | EP2816055B1 (cs) |
| JP (4) | JP5624027B2 (cs) |
| KR (4) | KR101666631B1 (cs) |
| CN (2) | CN102143970B (cs) |
| AU (1) | AU2009258054B2 (cs) |
| BR (1) | BRPI0912141A2 (cs) |
| CA (2) | CA2726076C (cs) |
| DK (2) | DK2297178T3 (cs) |
| ES (2) | ES2492670T3 (cs) |
| IL (3) | IL209369A (cs) |
| MX (3) | MX2010012990A (cs) |
| PT (2) | PT2297178E (cs) |
| RU (1) | RU2496786C2 (cs) |
| TR (1) | TR201903610T4 (cs) |
| WO (1) | WO2009151708A2 (cs) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR201903610T4 (tr) * | 2008-05-27 | 2019-03-21 | Genzyme Corp | Alfa-melanosit uyarici hormonlarin peptid analoglari. |
| CN101914138A (zh) * | 2010-07-13 | 2010-12-15 | 华东师范大学 | 一种用偶联剂制得的肝癌靶向肽-阿霉素及合成方法 |
| CN102008732B (zh) * | 2010-11-08 | 2012-10-24 | 武汉华耀生物医药有限公司 | 一种叶酸偶联抗体药物及其制备方法与应用 |
| US9441013B2 (en) | 2011-05-17 | 2016-09-13 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Melanocortin 1 receptor ligands and methods of use |
| US9434764B2 (en) | 2012-11-21 | 2016-09-06 | University Of Cincinnati | Skin care compositions and methods comprising selective agonists of melanocortin 1 receptor |
| WO2015067503A1 (en) * | 2013-11-07 | 2015-05-14 | Clinuvel Ag | Alpha-msh analogues for use in the treatment of psoriasis |
| US20170360896A1 (en) * | 2014-10-28 | 2017-12-21 | Clinuvel Ag | Inflammatory disease |
| AU2016298175B2 (en) | 2015-07-28 | 2022-01-06 | University Of Iowa Research Foundation | Compositions and methods of treating cancer |
| SG10201506686WA (en) * | 2015-08-24 | 2017-03-30 | Agency Science Tech & Res | Conjugates |
| CN106905432B (zh) * | 2015-12-18 | 2018-12-21 | 兰州大学 | 一种α促黑素细胞激素的融合蛋白及其制备方法和应用 |
| WO2017189860A1 (en) * | 2016-04-27 | 2017-11-02 | The Regents Of The University Of California | Preparation of functional homocysteine residues in polypeptides and peptides |
| US11179484B2 (en) | 2016-06-24 | 2021-11-23 | University Of Iowa Research Foundation | Compositions and methods of treating melanoma |
| AU2017340816C1 (en) * | 2016-10-04 | 2022-02-10 | Dsm Ip Assets B.V. | Melanocortin-1-receptor agonists |
| KR101957014B1 (ko) * | 2017-04-18 | 2019-06-20 | 순천대학교 산학협력단 | 항염증 활성을 나타내는 펩타이드 및 이를 유효성분으로 포함하는 항염증용 조성물 |
| CA3155131A1 (en) | 2019-09-23 | 2021-04-01 | Dds Research Inc. | Lipid vesicle compositions with penetration enhancing agents |
| US11529335B2 (en) | 2020-07-31 | 2022-12-20 | University Of Iowa Research Foundation | Compositions and methods for treating cancer |
| RU2766340C1 (ru) * | 2021-02-10 | 2022-03-15 | Игорь Закванович Зайцев | Пептидный толерогенный компаунд |
| KR20240035939A (ko) * | 2021-03-24 | 2024-03-19 | 글로 파마, 인크. | 피부 색소침착을 감소시키기 위한 펩타이드 및 방법 |
| WO2023091689A1 (en) | 2021-11-19 | 2023-05-25 | University Of Iowa Research Foundation | Combined use of mcr1-directed radiotherapy and immune checkpoint inhibition in the treatment of melanoma |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4894443A (en) | 1984-02-08 | 1990-01-16 | Cetus Corporation | Toxin conjugates |
| US4542225A (en) * | 1984-08-29 | 1985-09-17 | Dana-Farber Cancer Institute, Inc. | Acid-cleavable compound |
| US4952394A (en) | 1987-11-23 | 1990-08-28 | Bristol-Myers Company | Drug-monoclonal antibody conjugates |
| US5194425A (en) * | 1988-06-23 | 1993-03-16 | Anergen, Inc. | Mhc-mediated toxic conjugates useful in ameliorating autoimmunity |
| US5137877B1 (en) * | 1990-05-14 | 1996-01-30 | Bristol Myers Squibb Co | Bifunctional linking compounds conjugates and methods for their production |
| US5618528A (en) * | 1994-02-28 | 1997-04-08 | Sterling Winthrop Inc. | Biologically compatible linear block copolymers of polyalkylene oxide and peptide units |
| US5612474A (en) * | 1994-06-30 | 1997-03-18 | Eli Lilly And Company | Acid labile immunoconjugate intermediates |
| AU3374795A (en) | 1994-08-29 | 1996-03-22 | Prizm Pharmaceuticals, Inc. | Conjugates of vascular endothelial growth factor with targeted agents |
| US5716928A (en) * | 1995-06-07 | 1998-02-10 | Avmax, Inc. | Use of essential oils to increase bioavailability of oral pharmaceutical compounds |
| US5858401A (en) * | 1996-01-22 | 1999-01-12 | Sidmak Laboratories, Inc. | Pharmaceutical composition for cyclosporines |
| WO1998002192A1 (en) * | 1996-07-12 | 1998-01-22 | Immunomedics, Inc. | Radiometal-binding peptide analogues |
| US6350430B1 (en) | 1997-10-27 | 2002-02-26 | Lion Bioscience Science Ag | Melanocortin receptor ligands and methods of using same |
| US7157418B1 (en) | 1998-07-22 | 2007-01-02 | Osprey Pharmaceuticals, Ltd. | Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders |
| US20020193332A1 (en) * | 2001-02-12 | 2002-12-19 | Hedley Mary Lynne | Methods of treating bladder disorders |
| US6969702B2 (en) * | 2002-11-20 | 2005-11-29 | Neuronova Ab | Compounds and methods for increasing neurogenesis |
| WO2005120588A2 (en) * | 2004-05-26 | 2005-12-22 | The Curators Of The University Of Missouri | Peptides delivered to cell nuclei |
| KR101232201B1 (ko) * | 2005-07-08 | 2013-02-12 | 입센 파마 에스.에이.에스 | 멜라노코르틴 수용체 리간드 |
| US20100009340A1 (en) * | 2006-04-05 | 2010-01-14 | The Regents Of The University Of California | Compositions and methods for the analysis and treatment of aids wasting syndrome and immune cell dysfunction |
| FR2914646A1 (fr) * | 2007-04-04 | 2008-10-10 | Neorphys Soc Par Actions Simpl | Analogues peptidiques des recepteurs des melanocortines |
| US8069129B2 (en) * | 2007-04-10 | 2011-11-29 | Ab Initio Technology Llc | Editing and compiling business rules |
| CN101302245B (zh) * | 2007-05-09 | 2011-11-16 | 中国人民解放军军事医学科学院毒物药物研究所 | 黑色素皮质激素受体四肽类激动剂及其制备方法和用途 |
| TR201903610T4 (tr) | 2008-05-27 | 2019-03-21 | Genzyme Corp | Alfa-melanosit uyarici hormonlarin peptid analoglari. |
-
2009
- 2009-03-20 TR TR2019/03610T patent/TR201903610T4/tr unknown
- 2009-03-20 ES ES09763002.4T patent/ES2492670T3/es active Active
- 2009-03-20 CA CA2726076A patent/CA2726076C/en not_active Expired - Fee Related
- 2009-03-20 WO PCT/US2009/037809 patent/WO2009151708A2/en active Application Filing
- 2009-03-20 CN CN200980120892.6A patent/CN102143970B/zh not_active Expired - Fee Related
- 2009-03-20 KR KR1020107029335A patent/KR101666631B1/ko active IP Right Grant
- 2009-03-20 JP JP2011511661A patent/JP5624027B2/ja not_active Expired - Fee Related
- 2009-03-20 BR BRPI0912141A patent/BRPI0912141A2/pt not_active IP Right Cessation
- 2009-03-20 CN CN201611160601.4A patent/CN107098957A/zh active Pending
- 2009-03-20 MX MX2010012990A patent/MX2010012990A/es active IP Right Grant
- 2009-03-20 AU AU2009258054A patent/AU2009258054B2/en not_active Ceased
- 2009-03-20 CA CA2998948A patent/CA2998948A1/en not_active Abandoned
- 2009-03-20 PT PT97630024T patent/PT2297178E/pt unknown
- 2009-03-20 EP EP14178968.5A patent/EP2816055B1/en active Active
- 2009-03-20 RU RU2010153217/04A patent/RU2496786C2/ru not_active IP Right Cessation
- 2009-03-20 EP EP09763002.4A patent/EP2297178B1/en active Active
- 2009-03-20 DK DK09763002.4T patent/DK2297178T3/da active
- 2009-03-20 ES ES14178968T patent/ES2715329T3/es active Active
- 2009-03-20 DK DK14178968.5T patent/DK2816055T3/en active
- 2009-03-20 MX MX2013012525A patent/MX356295B/es unknown
- 2009-03-20 KR KR1020177023883A patent/KR20170102050A/ko active Application Filing
- 2009-03-20 KR KR1020167020183A patent/KR101810110B1/ko active IP Right Grant
- 2009-03-20 PT PT14178968T patent/PT2816055T/pt unknown
- 2009-03-20 US US12/408,560 patent/US8440793B2/en active Active
- 2009-03-20 KR KR1020187030624A patent/KR20180118250A/ko not_active Application Discontinuation
-
2010
- 2010-11-17 IL IL209369A patent/IL209369A/en not_active IP Right Cessation
- 2010-11-26 MX MX2018006299A patent/MX2018006299A/es unknown
-
2013
- 2013-05-08 US US13/890,039 patent/US9115174B2/en active Active
-
2014
- 2014-07-24 JP JP2014150428A patent/JP6170019B2/ja not_active Expired - Fee Related
-
2015
- 2015-08-19 US US14/830,572 patent/US9738698B2/en active Active
-
2016
- 2016-05-29 IL IL245906A patent/IL245906A0/en unknown
-
2017
- 2017-01-05 JP JP2017000343A patent/JP6585099B2/ja not_active Expired - Fee Related
- 2017-05-01 IL IL252058A patent/IL252058A0/en unknown
- 2017-07-10 US US15/645,974 patent/US10385108B2/en active Active
-
2019
- 2019-02-04 JP JP2019017752A patent/JP2019065053A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011521949A5 (cs) | ||
| RU2010153217A (ru) | Пептидные аналоги альфа-меланоцитстимулирующего гормона | |
| JP5358564B2 (ja) | 環状ペプチドｃｘｃｒ４アンタゴニスト | |
| ES2302390T3 (es) | Analogos de glp-1. | |
| US6242563B1 (en) | Peptide analogues | |
| JP2017535527A5 (cs) | ||
| EP1098906B1 (en) | Peptide analogues of pacap | |
| JP2016515620A5 (cs) | ||
| CA2399187C (en) | Kahalalide compounds | |
| CZ20011748A3 (cs) | Sloučenina, farmaceutický prostředek a pouľití sloučeniny | |
| Novoa et al. | Variation of the net charge, lipophilicity, and side chain flexibility in Dmt1-DALDA: effect on opioid activity and biodistribution | |
| WO2018128828A1 (en) | Novel hepcidin mimetics and uses thereof | |
| CA2532994A1 (en) | C5a receptor antagonists | |
| Grieco et al. | Novel α-melanocyte stimulating hormone peptide analogues with high candidacidal activity | |
| US20240209023A1 (en) | Peptide compound, application thereof and composition containing same | |
| KR20010033103A (ko) | 인테그린 억제제 성질을 가진 시클로펩티드 유도체 | |
| CA2378778A1 (en) | Il-16 antagonists | |
| Yan et al. | Structure-activity relationships of β-MSH derived melanocortin-4 receptor peptide agonists | |
| Kashkin et al. | A new tridecapeptide with an octaarginine vector has analgesic therapeutic potential and prevents morphine-induced tolerance | |
| WO2022177878A1 (en) | Glucagon-like peptide-1 receptor antagonists | |
| JPH07233084A (ja) | 化学療法剤効果増強剤 | |
| WO2022069557A3 (en) | Amidated peptides and their deamidated counterparts displayed by hla-a*02 for use in immunotherapy against different types of cancers |